The collaboration will launch a portfolio of products in ophthalmology, cardio-metabolic and oncology therapeutic categories in the fourth quarter of 2023. Credit: Lotus.
Lotus Pharmaceuticals and Teraju Pharma have
entered a strategic partnership
to market Lotus’s products in a range of therapeutic areas in Malaysia.
Teraju Pharma will be responsible for marketing and promoting the products using its relationships and infrastructure.
Recommended Reports
Reports
Malaysia - Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and...
GlobalData
Reports
Impact of India on the Pharmaceutical Industry - Thematic Research
GlobalData
View all
The company is a specialised pharmaceutical wholesaler and holds a licence, issued by the country’s ministry of health, to import non-registered pharmaceutical products, orphan drugs and other life-saving medicines.
It sources a wide range of branded or generic equivalent drugs from across the globe to meet the needs of the local market.
Lotus Pharmaceuticals CEO Petar Vazharov stated: “We are delighted at our new collaboration with Teraju.
“This partnership will enable us to establish a substantial presence in Malaysia, particularly in the oncology sector, which leverages high-quality manufacturing and a rich pipeline of products.”
The company confirmed that the alliance is in line with its strategic plan to expand in Southeast Asia.
The collaboration will launch a portfolio of products in the therapeutic categories of ophthalmology, cardio-metabolic and oncology, commencing in the fourth quarter of 2023.
Lotus Pharmaceuticals, Alvogen and NRx Pharmaceuticals recently
signed a global collaboration agreement
for the development and commercialisation of NRX-101 to treat suicidal treatment-resistant bipolar depression (S-TRBD).
The company will buy worldwide rights for the therapy and handle its commercialisation activities in markets outside the US.
